Report
Paul de Froment ...
  • Sebastián Marroquin Mérida
  • Thomas Mordelle

Nel: tapping further on US subsidies

Yesterday, Nel announced additional support from the US DoE and the state of Michigan regarding its 4GW electrolyser production plant project in the country. USD75m in cash incentives and grants will be made available to Nel at the time of the project's FID. This adds to last year's USD50m US DoE s
Underlying
NEL ASA

NEL ASA develops diagnostic tests for early detection of diseases. Co.'s patented method is based on identifying disease-specific gene expression signatures from sample materials, such as blood. Co.'s products in development phase include MCItect, for patients with Mild Cognitive Impairment (MCI) aimed to detect Alzheimer disease within two years prior to onset of dementia, and ADtect, for the detection of mild to moderate Alzheimer disease, as well as one project in discovery phase, namely AMYtect, for brain amyloid detection.

Provider
Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Analysts
Paul de Froment

Sebastián Marroquin Mérida

Thomas Mordelle

Other Reports on these Companies
Other Reports from Bryan Garnier

ResearchPool Subscriptions

Get the most out of your insights

Get in touch